Welcome to SuperLan Chemical Co.,Ltd.
Home > Products > Angiogenesis > HIF > KC7F2

KC7F2

(CAS No:927822-86-4)
KC7F2 is a selective HIF-1α transcription inhibitor with IC50 of 20 μM in a cell-based assay.
CAS No:927822-86-4
Molecular Weight(MW):570.38
Purity:99.00%
Specification:500MG;1G;5G;10G;50G;100G
Price and large packaging, please e-mail consultation:info@SuperLan-chem.com
QC Documents
 COA  MSDS  HPLC  NMR
ChemicalInfomation
CAS No: 927822-86-4
Molecular formula(MF) C16H16Cl4N2O4S4
Molecular Weight(MW): 570.38
Alias
Solubility
In vitro DMSO 100 mg/mL (175.32 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo
Biological Activity
Description KC7F2 is a selective HIF-1α transcription inhibitor with IC50 of 20 μM in a cell-based assay.
Targets
HIF-1α [1]
20 μM
In vitro

KC7F2 inhibits HRE-driven transcription and decreases HIF-1α protein levels in LN229-HRE-AP cells. KC7F2 shows a dose-response cytotoxicity with IC50 of approximately 15 to 25 μM in cancer cells MCF7, LNZ308, A549, U251MG, and LN229. In D54MG glioma cells, KC7F2 inhibits colony formation, especially under hypoxia. [1] In hypoxic microglial cultures, KC7F2 downregulates the expression of TfR and DMT, and reduces the HIF-1α mediated iron accumulation. [2]

In vivo KC7F2 significantly reduces the latent period in the pentylenetetrazole kindling rat model and increases the rate of spontaneous recurrent seizures during the chronic stage in the lithium-pilocarpine rat model. [3]